Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis (IBIS-PC)
27 sierpnia 2026 zaktualizowane przez: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A Prospective, Multicenter, Open-Label, Randomized, Parallel-Group, Noninferiority Trial of MRI/Ultrasound Cognitive Fusion Targeted Biopsy Combined With Ipsilateral Versus Bilateral Systematic Biopsy for Prostate Cancer Diagnosis
Prostate biopsy usually combines magnetic resonance imaging/ultrasound (MRI/US) cognitive fusion targeted biopsy with systematic biopsy. Standard bilateral systematic biopsy requires sampling from both sides of the prostate and may increase the number of biopsy cores, procedural discomfort, procedure time, pathological workload, and biopsy-related complications.
This prospective, multicenter, open-label, randomized noninferiority trial will enroll 454 biopsy-naive men with suspected prostate cancer, a unilateral prostate MRI lesion with a highest PI-RADS score of 4 or 5, and prostate-specific antigen levels of 20 ng/mL or lower. Participants will be randomly assigned in a 1:1 ratio to receive transperineal MRI/US cognitive fusion targeted biopsy combined with either a 6-core ipsilateral systematic biopsy or a standard 12-core bilateral systematic biopsy.
The primary objective is to determine whether the ipsilateral systematic biopsy strategy is noninferior to the bilateral systematic biopsy strategy for detecting clinically significant prostate cancer, defined as International Society of Urological Pathology Grade Group 2 or higher. The study will also compare overall prostate cancer detection, biopsy core numbers, pain and discomfort, procedure time, pathological workload and costs, urinary symptoms, quality of life, and biopsy-related adverse events and complications through 30 days after biopsy.
Przegląd badań
Status
Rekrutacyjny
Warunki
Typ studiów
Interwencyjne
Zapisy (Szacowany)
454
Faza
- Nie dotyczy
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Kontakt w sprawie studiów
- Nazwa: Haifeng Huang
- Numer telefonu: +86-186-5165-8099
- E-mail: 24083491@qq.com
Lokalizacje studiów
-
-
Jiangsu
-
Nanjing, Jiangsu, Chiny
- Rekrutacyjny
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
-
Kontakt:
- Haifeng Huang
- Numer telefonu: +86-186-5165-8099
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Nie
Opis
Inclusion Criteria:
- Male participants older than 18 years.
- Suspected prostate cancer and scheduled to undergo transperineal prostate biopsy.
- Prostate MRI showing a unilateral lesion with a highest Prostate Imaging Reporting and Data System (PI-RADS) score of 4 or 5.
- Serum prostate-specific antigen (PSA) level of 20 ng/mL or lower.
- Able to tolerate and undergo transperineal prostate biopsy.
- Willing to participate in the study and able to provide written informed consent.
Exclusion Criteria:
- Prior prostate biopsy.
- Prior prostate-related treatment or procedure that may affect pathological assessment or interpretation of the biopsy results, including but not limited to androgen deprivation therapy for prostate cancer, radiotherapy, focal therapy, or transurethral prostate surgery.
- Prostate MRI showing a lesion crossing the prostatic midline such that the lesion side cannot be clearly determined, or an independent contralateral lesion with a PI-RADS score of 3 or higher.
- Acute urinary tract infection, severe coagulation disorder, or any other contraindication to transperineal prostate biopsy.
- In the investigator's judgment, inability to understand the study, comply with study procedures, or provide written informed consent.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: TB+iSB
Participants will undergo transperineal MRI/ultrasound cognitive fusion targeted biopsy of all PI-RADS 3 or higher lesions on the MRI lesion side, with 3 targeted cores obtained from each lesion.
Targeted biopsy will be followed by a 6-core ipsilateral systematic biopsy covering the medial and lateral regions of the base, midgland, and apex on the MRI lesion side.
Local anesthesia will be administered only on the MRI lesion side.
|
Transperineal MRI/ultrasound cognitive fusion targeted biopsy will be performed for all PI-RADS 3 or higher lesions on the MRI lesion side, with 3 cores obtained from each lesion.
This will be followed by a 6-core systematic biopsy limited to the MRI lesion side, sampling the medial and lateral regions of the base, midgland, and apex.
Local anesthesia will be limited to the MRI lesion side.
|
|
Aktywny komparator: TB+SB
Participants will undergo transperineal MRI/ultrasound cognitive fusion targeted biopsy of all PI-RADS 3 or higher lesions on the MRI lesion side, with 3 targeted cores obtained from each lesion.
Targeted biopsy will be followed by a standard 12-core bilateral systematic biopsy covering the medial and lateral regions of the base, midgland, and apex on both sides of the prostate.
Bilateral local anesthesia will be administered.
|
Transperineal MRI/ultrasound cognitive fusion targeted biopsy will be performed for all PI-RADS 3 or higher lesions on the MRI lesion side, with 3 cores obtained from each lesion.
This will be followed by a standard 12-core bilateral systematic biopsy sampling the medial and lateral regions of the base, midgland, and apex on both sides of the prostate.
Bilateral local anesthesia will be administered.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Detection Rate of Clinically Significant Prostate Cancer
Ramy czasowe: Day 14 after biopsy
|
The proportion of participants with clinically significant prostate cancer detected by the assigned biopsy strategy.
Clinically significant prostate cancer is defined as biopsy pathology showing International Society of Urological Pathology (ISUP) Grade Group 2 or higher.
The between-group risk difference will be calculated as TB+iSB minus TB+SB.
Noninferiority will be concluded if the lower bound of the two-sided 95% confidence interval is greater than -15%.
|
Day 14 after biopsy
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Prostate Cancer Detection Rate
Ramy czasowe: Day 14 after biopsy
|
The proportion of participants with prostate cancer detected on any biopsy specimen, regardless of ISUP Grade Group.
|
Day 14 after biopsy
|
|
Clinically Insignificant Prostate Cancer Detection Rate
Ramy czasowe: Day 14 after biopsy
|
The proportion of participants with biopsy pathology showing ISUP Grade Group 1 prostate cancer and no lesion with ISUP Grade Group 2 or higher.
|
Day 14 after biopsy
|
|
High-Grade Prostate Cancer Detection Rate
Ramy czasowe: Day 14 after biopsy
|
The proportion of participants with biopsy pathology showing ISUP Grade Group 3 or higher.
|
Day 14 after biopsy
|
|
Pain Numeric Rating Scale Score
Ramy czasowe: Within 30 minutes after biopsy and at 24 hours after biopsy; additionally at day 7 (±2 days) among participants with persistent pain
|
Biopsy-related pain associated with local anesthesia, needle puncture, and biopsy core acquisition will be assessed using an 11-point Numeric Rating Scale ranging from 0 to 10.
A score of 0 indicates no pain and a score of 10 indicates the worst imaginable pain.
Higher scores indicate greater pain.
|
Within 30 minutes after biopsy and at 24 hours after biopsy; additionally at day 7 (±2 days) among participants with persistent pain
|
|
Overall Discomfort Numeric Rating Scale Score
Ramy czasowe: Within 30 minutes after biopsy and at 24 hours after biopsy; additionally at day 7 (±2 days) among participants with persistent discomfort
|
Overall procedural discomfort related to instrument insertion, ultrasound positioning or pressure, prostatic pressure, pelvic floor traction, foreign-body sensation, positioning, and the biopsy procedure will be assessed using an 11-point Numeric Rating Scale ranging from 0 to 10.
A score of 0 indicates no discomfort and a score of 10 indicates the worst imaginable discomfort.
Higher scores indicate greater discomfort.
|
Within 30 minutes after biopsy and at 24 hours after biopsy; additionally at day 7 (±2 days) among participants with persistent discomfort
|
|
Procedure Time
Ramy czasowe: During the biopsy procedure
|
Procedure time in minutes, measured from the start of local anesthesia to completion of the final biopsy core.
For the TB+iSB group, timing begins when local anesthesia is started on the MRI lesion side.
For the TB+SB group, timing begins when bilateral local anesthesia is started.
|
During the biopsy procedure
|
|
Total Number of Biopsy Cores
Ramy czasowe: During the biopsy procedure
|
The total number of biopsy cores, including MRI-targeted and systematic biopsy cores, obtained for each participant will be recorded.
|
During the biopsy procedure
|
|
Number of Pathology Specimen Containers
Ramy czasowe: Periprocedural
|
The total number of pathology specimen containers generated from the biopsy procedure will be recorded for each participant.
|
Periprocedural
|
|
Total Pathology-Related Costs
Ramy czasowe: Up to 2 weeks after biopsy
|
Total pathology-related costs associated with biopsy specimen handling, processing, histological examination, and pathology reporting will be obtained from the applicable hospital records for each participant.
|
Up to 2 weeks after biopsy
|
|
Incidence of Biopsy-Related Adverse Events and Complications
Ramy czasowe: From biopsy through 30 days after biopsy; assessed within 30 minutes, at 24 hours, day 7 (±2 days), and day 30 (±7 days)
|
The proportion of participants experiencing any biopsy-related adverse event or complication will be assessed.
Events include gross hematuria, hematospermia, perineal hematoma, fever or infection, urinary retention, syncope, emergency department visits, unplanned or prolonged hospitalization, serious adverse events, and additional medical interventions required because of a complication.
|
From biopsy through 30 days after biopsy; assessed within 30 minutes, at 24 hours, day 7 (±2 days), and day 30 (±7 days)
|
|
Severity of Biopsy-Related Complications by Clavien-Dindo Grade
Ramy czasowe: From biopsy through 30 days after biopsy
|
The maximum Clavien-Dindo grade of biopsy-related complications will be recorded for each participant.
Grades range from I to V, with higher grades indicating greater severity: Grade I indicates a minor deviation from the expected postoperative course; Grade II requires pharmacological treatment; Grade III requires an intervention; Grade IV indicates a life-threatening complication requiring intensive care; and Grade V indicates death.
|
From biopsy through 30 days after biopsy
|
|
Change From Baseline in International Prostate Symptom Score
Ramy czasowe: Baseline and 7 days after biopsy (±2 days)
|
The International Prostate Symptom Score consists of 7 questions assessing lower urinary tract symptoms.
The total score ranges from 0 to 35, with higher scores indicating more severe urinary symptoms.
Change from baseline will be calculated as the score at 7 days after biopsy minus the baseline score.
|
Baseline and 7 days after biopsy (±2 days)
|
|
Change From Baseline in IPSS Quality of Life Score
Ramy czasowe: Baseline and 7 days after biopsy (±2 days)
|
The quality of life question associated with the International Prostate Symptom Score ranges from 0 to 6, with higher scores indicating greater dissatisfaction with the participant's urinary condition.
Change from baseline will be calculated as the score at 7 days after biopsy minus the baseline score.
|
Baseline and 7 days after biopsy (±2 days)
|
|
Number of Histology Slides
Ramy czasowe: Up to 2 weeks after biopsy
|
The total number of histology slides generated for biopsy specimen processing and pathological diagnosis will be recorded for each participant.
|
Up to 2 weeks after biopsy
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Real-Time Ultrasound Visibility of MRI-Suspicious Lesions
Ramy czasowe: During MRI/ultrasound cognitive fusion targeted biopsy
|
Each MRI-suspicious lesion designated as L1, L2, or L3 will be classified according to whether it can be identified on real-time ultrasound during MRI/ultrasound cognitive fusion targeted biopsy.
Categories are visible, not visible, uncertain, and not applicable.
The number and proportion of MRI-suspicious lesions in each category will be reported.
|
During MRI/ultrasound cognitive fusion targeted biopsy
|
|
ISUP Grade Group Concordance Between Biopsy and Radical Prostatectomy Pathology
Ramy czasowe: Up to 6 months after biopsy
|
Among participants who undergo radical prostatectomy, the relationship between biopsy ISUP Grade Group and radical prostatectomy ISUP Grade Group will be classified into three mutually exclusive categories: concordant, upgraded, or downgraded.
Concordant is defined as the same ISUP Grade Group on biopsy and radical prostatectomy pathology; upgraded is defined as a higher ISUP Grade Group on radical prostatectomy pathology than on biopsy pathology; and downgraded is defined as a lower ISUP Grade Group on radical prostatectomy pathology than on biopsy pathology.
The number and proportion of participants in each category will be reported.
|
Up to 6 months after biopsy
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
20 lipca 2026
Zakończenie podstawowe (Szacowany)
1 marca 2027
Ukończenie studiów (Szacowany)
1 kwietnia 2027
Daty rejestracji na studia
Pierwszy przesłany
5 sierpnia 2026
Pierwszy przesłany, który spełnia kryteria kontroli jakości
27 sierpnia 2026
Pierwszy wysłany (Rzeczywisty)
31 sierpnia 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
31 sierpnia 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
27 sierpnia 2026
Ostatnia weryfikacja
1 lipca 2026
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- IUNU-PC-131
- 2026-0723-02 (Inny identyfikator: Medical Ethics Committee of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
NIEZDECYDOWANY
Opis planu IPD
An individual participant data sharing plan has not yet been finalized.
Any future sharing of de-identified participant data will be considered only with approval from the sponsor and the relevant ethics committee and in accordance with applicable laws, regulations, and privacy protection requirements.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .